Leqembi is an infusion therapy that targets and removes the beta-amyloid plaque that builds up in the brains of Alzheimer's ...

Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband ...

An appointment with Wendell Helveston, M.D., a neurologist in Hattiesburg, MS, led to a series of diagnostic tests, such as ...

In a major Phase 3 clinical trial, lecanemab showed it could slow the decline in memory and thinking ability by 27% overall ...

So, what’s really going on? In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company ...

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing symptoms by 50%.

Leqembi (lecanemab-irmb) is a brand-name drug prescribed to treat Alzheimer’s disease in adults with mild cognitive impairment or mild dementia. The drug comes as an intravenous (IV) infusion ...

A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was totally ineffective in ...

A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...

In 2020, Sue volunteered for a study at the Washington University School of Medicine in St. Louis. Researchers there were conducting part of a nationwide clinical trial of Leqembi, then known by ...